Method for renal disease diagnosis and prognosis using annexin a1 and rab23 as markers

This invention discloses use of Annexin A1 or Rab23 as a biomarker for diagnosing kidney disease or assessing efficacy of kidney disease treatment. The diagnosing method of this invention is for determining whether the subject suffers from or is at risk for a renal disorder (e.g., kidney sclerosis,...

Full description

Saved in:
Bibliographic Details
Main Authors CHEN, AN, JIA, SHU-MIN, SHUI, HAO-AI
Format Patent
LanguageChinese
English
Published 16.08.2010
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS OR TEST PAPERS THEREFOR
CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES
ENZYMOLOGY
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
PHYSICS
PROCESSES OF PREPARING SUCH COMPOSITIONS
SPIRITS
TESTING
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:This invention discloses use of Annexin A1 or Rab23 as a biomarker for diagnosing kidney disease or assessing efficacy of kidney disease treatment. The diagnosing method of this invention is for determining whether the subject suffers from or is at risk for a renal disorder (e.g., kidney sclerosis, kidney fibrosis, glomerular injury, kidney failure, glomerulosclerosis, or glomerulonephritis).
Bibliography:Application Number: TW200998104215